{"id":345915,"date":"2025-08-25T09:05:40","date_gmt":"2025-08-25T09:05:40","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-structure-therapeutics\/"},"modified":"2025-08-25T09:05:40","modified_gmt":"2025-08-25T09:05:40","slug":"how-to-buy-structure-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/","title":{"rendered":"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-345915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Structure Therapeutics Inc. (GPCR) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. Fiyat analizi ve ticaret stratejileri ile eksiksiz yat\u0131r\u0131m rehberi.","description_source":{"label":"Description","type":"textarea","formatted_value":"Structure Therapeutics Inc. (GPCR) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. Fiyat analizi ve ticaret stratejileri ile eksiksiz yat\u0131r\u0131m rehberi."},"intro":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Structure Therapeutics Inc. (GPCR), obezite ve metabolik hastal\u0131klar i\u00e7in yenilik\u00e7i oral tedavileriyle dikkat \u00e7ekiyor. Klinik a\u015famadaki bu biyofarma, kronik hastal\u0131klar\u0131n tedavisinde devrim yaratabilir ve ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar bunu yak\u0131ndan takip ediyor. Bu heyecan verici yat\u0131r\u0131m f\u0131rsat\u0131 hakk\u0131nda bilmeniz gereken her \u015feyi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Structure Therapeutics Inc. (GPCR), obezite ve metabolik hastal\u0131klar i\u00e7in yenilik\u00e7i oral tedavileriyle dikkat \u00e7ekiyor. Klinik a\u015famadaki bu biyofarma, kronik hastal\u0131klar\u0131n tedavisinde devrim yaratabilir ve ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar bunu yak\u0131ndan takip ediyor. Bu heyecan verici yat\u0131r\u0131m f\u0131rsat\u0131 hakk\u0131nda bilmeniz gereken her \u015feyi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Structure Therapeutics Hisse Senedi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Structure Therapeutics Inc. (GPCR), NASDAQ borsas\u0131nda <strong>19,37 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize <strong>13 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin - \u015firketin bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn. Bu tarih, klinik deneme g\u00fcncellemeleri ve finansal performansa ba\u011fl\u0131 olarak hisse fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir.<\/p> <p><strong>13 Kas\u0131m Neden \u00d6nemli:<\/strong><br> 6 A\u011fustos 2025 tarihli \u00f6nceki kazan\u00e7 raporu, 2024'te 22,1 milyon dolardan 54,7 milyon dolara y\u00fckselen Ar-Ge harcamalar\u0131n\u0131 ve 61,7 milyon dolarl\u0131k net zarar\u0131 g\u00f6sterdi. Zararlar\u0131na ra\u011fmen, \u015firket 786,5 milyon dolarl\u0131k g\u00fc\u00e7l\u00fc bir nakit pozisyonuna sahip ve operasyonlar\u0131 2027'ye kadar finanse etmesi bekleniyor (<a href=\"https:\/\/www.stocktitan.net\/news\/GPCR\/structure-therapeutics-reports-second-quarter-2025-financial-results-lhkttczruz5p.html\">2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/a>).<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd0d Klinik Haberlerine Tarihsel Fiyat Tepkisi<\/h2> <p>GPCR gibi biyoteknoloji hisseleri, klinik deneme duyurular\u0131 etraf\u0131nda genellikle \u00f6nemli fiyat hareketleri ya\u015far. \u0130\u015fte hisse senedinin son geli\u015fmelere verdi\u011fi tepkiler:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Fiyat De\u011fi\u015fimi<\/th><th>Etki S\u00fcresi<\/th><\/tr> <\/thead> <tbody> <tr><td>A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7 A\u00e7\u0131klamas\u0131<\/td><td>-%8 (takip eden hafta)<\/td><td>2 hafta<\/td><\/tr> <tr><td>Haz 2025<\/td><td>ADA Bilimsel Oturumlar\u0131<\/td><td>+%12<\/td><td>3 g\u00fcn<\/td><\/tr> <tr><td>Nis 2025<\/td><td>Klinik Program Geni\u015flemesi<\/td><td>+%15<\/td><td>1 hafta<\/td><\/tr> <tr><td>\u015eub 2025<\/td><td>Faz 2 Deneme G\u00fcncellemeleri<\/td><td>+%22<\/td><td>10 g\u00fcn<\/td><\/tr> <\/tbody> <\/table> <p>Model, olumlu klinik geli\u015fmelerin genellikle anl\u0131k fiyat s\u0131\u00e7ramalar\u0131na yol a\u00e7t\u0131\u011f\u0131n\u0131, finansal sonu\u00e7lar\u0131n ise daha \u00f6l\u00e7\u00fcl\u00fc tepkiler yaratt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>  <h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Performans Analizi<\/h2> <p>Structure Therapeutics son alt\u0131 ayda olduk\u00e7a dalgal\u0131 bir seyir izledi:<\/p> <ul> <li><strong>\u015eubat 2025:<\/strong> Hisse 31,33 $ ile zirve yapt\u0131ktan sonra d\u00fc\u015ft\u00fc<\/li> <li><strong>Mart 2025:<\/strong> Piyasa volatilitesi nedeniyle 17,24 $ seviyesine geriledi<\/li> <li><strong>Nisan 2025:<\/strong> 13,22 $ ile dip yapt\u0131 ve ard\u0131ndan g\u00fc\u00e7l\u00fc bir toparlanma ya\u015fad\u0131<\/li> <li><strong>May\u0131s-Haziran 2025:<\/strong> 21-23 $ aral\u0131\u011f\u0131nda istikrar sa\u011flad\u0131<\/li> <li><strong>Temmuz-A\u011fustos 2025:<\/strong> 18-20 $ aras\u0131nda i\u015flem g\u00f6r\u00fcrken son d\u00f6nemde art\u0131\u015f ya\u015fand\u0131<\/li> <\/ul> <p>Genel trend, \u015eubat zirvesinden itibaren <strong>%35 d\u00fc\u015f\u00fc\u015f<\/strong> g\u00f6sterse de, hisse son bir ayda <strong>%7,81 kazan\u00e7<\/strong> sa\u011flad\u0131 (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/structure-therapeutics-nasdaqgpcr-shares-gap-up-still-a-buy-2025-08-19\/\">Son Performans<\/a>). Bu volatilite, klinik a\u015famadaki biyoteknoloji \u015firketleri i\u00e7in tipiktir ve \u00f6nemli veri a\u00e7\u0131klamalar\u0131n\u0131 beklerken g\u00f6r\u00fcl\u00fcr.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Analist konsens\u00fcs\u00fc ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak beklentiler \u015funlard\u0131r:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu:<\/strong> 50-75 $ aral\u0131\u011f\u0131 (klinik verilere ba\u011fl\u0131 olarak)<\/li> <li><strong>2026 Projeksiyonu:<\/strong> 75-90 $ (Faz 3 ba\u015flang\u0131c\u0131 bekleniyor)<\/li> <li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc:<\/strong> 120-150 $ (potansiyel d\u00fczenleyici ba\u015fvurular)<\/li> <li><strong>2030 Vizyonu:<\/strong> 200 $+ (ticarile\u015fme a\u015famas\u0131)<\/li> <\/ul> <p>Ortalama analist fiyat hedefi <strong>75,63 $<\/strong> olup, mevcut seviyelerden <strong>%285 y\u00fckseli\u015f potansiyeli<\/strong> sunmaktad\u0131r (<a href=\"https:\/\/stockanalysis.com\/stocks\/gpcr\/forecast\/\">Analist Konsens\u00fcs\u00fc<\/a>). \u00c7o\u011fu analist \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi vermekte ve sadece olumlu \u00f6nerilerde bulunmaktad\u0131r.<\/p> <p><strong>Karar: AL<\/strong> - Risk-getiri oran\u0131, \u00f6zellikle \u00f6nemli klinik veri a\u00e7\u0131klamalar\u0131ndan \u00f6nce yat\u0131r\u0131m\u0131 desteklemektedir.<\/p>  <h2>\u26a0\ufe0f Dikkate Al\u0131nmas\u0131 Gereken Yat\u0131r\u0131m Riskleri<\/h2> <p>Structure Therapeutics Inc. (GPCR) hissesine yat\u0131r\u0131m yapmadan \u00f6nce \u015fu riskleri anlay\u0131n:<\/p> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131:<\/strong> \u00d6nc\u00fc ila\u00e7 aleniglipron, Faz 2 veya Faz 3 denemelerinde ba\u015far\u0131s\u0131z olabilir<\/li> <li><strong>D\u00fczenleyici Engeller:<\/strong> FDA onay\u0131 yeni ila\u00e7lar i\u00e7in asla garanti de\u011fildir<\/li> <li><strong>Rekabet:<\/strong> Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer oral GLP-1 ila\u00e7lar\u0131 geli\u015ftiriyor<\/li> <li><strong>Nakit T\u00fcketimi:<\/strong> \u00c7eyrek bazda 61,7 milyon dolarl\u0131k zarar, dikkatli sermaye y\u00f6netimi gerektirir<\/li> <li><strong>Piyasa Volatilitesi:<\/strong> Biyoteknoloji hisseleri tek bir haberle %20+ dalgalanabilir<\/li> <\/ul>  <h2>\ud83d\udfe2 2025 Yat\u0131r\u0131m\u0131 \u0130\u00e7in Olumlu Sinyaller<\/h2> <p>Risklere ra\u011fmen, yat\u0131r\u0131m i\u00e7in destekleyen birka\u00e7 fakt\u00f6r vard\u0131r:<\/p> <ul> <li><strong>786,5 Milyon $ Nakit Yedek:<\/strong> 2027'ye kadar operasyonlar\u0131 finanse eder, sermaye art\u0131r\u0131m\u0131 gerektirmez<\/li> <li><strong>Oral \u0130la\u00e7 Avantaj\u0131:<\/strong> Enjekte edilebilir rakiplere kar\u015f\u0131 potansiyel oyun de\u011fi\u015ftirici<\/li> <li><strong>Geni\u015fleyen Klinik Program:<\/strong> Rekabet\u00e7i konumu g\u00fc\u00e7lendiren \u00fc\u00e7 yeni klinik \u00e7al\u0131\u015fma<\/li> <li><strong>Analist Deste\u011fi:<\/strong> %95 al\u0131m \u00f6nerisi ve y\u00fcksek fiyat hedefleri<\/li> <li><strong>Piyasa Zamanlamas\u0131:<\/strong> 2025 sonuna kadar beklenen \u00f6nemli veriler b\u00fcy\u00fcmeyi tetikleyebilir<\/li> <\/ul>  <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-5'ini y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131r\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> T\u00fcm yat\u0131r\u0131m\u0131 tek seferde de\u011fil, par\u00e7a par\u00e7a yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun:<\/strong> Daha iyi giri\u015f noktalar\u0131 i\u00e7in 18 $ alt\u0131 d\u00fc\u015f\u00fc\u015fleri takip edin<\/li> <li><strong>Volatiliteye Haz\u0131rlan\u0131n:<\/strong> Hem olumlu hem olumsuz haberler i\u00e7in plan\u0131n\u0131z olsun<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc:<\/strong> \"Biyoteknoloji hisseleriyle ticaret yapmak, fl\u00f6rt etmek gibidir - Faz 3 sonu\u00e7lar\u0131 gelene kadar heyecan vericidir. Her zaman bir \u00e7\u0131k\u0131\u015f stratejiniz olsun!\"<\/li> <\/ol>  <h2>\u2705 Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeli hisseleri sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Risk alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"GPCR\" Aramas\u0131 Yap\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>\u0130\u015flem \u00f6ncesi komisyon \u00fccretlerini kontrol edin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2> <p>Structure Therapeutics Inc. (GPCR) hisseleri nas\u0131l al\u0131n\u0131r diye d\u00fc\u015f\u00fcnenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma:<\/strong> Ticarete ba\u015flamak i\u00e7in sadece 5 $<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama:<\/strong> Tek belge y\u00fcklemesi ile KYC tamamlan\u0131r<\/li> <li><strong>\u00c7oklu Para \u00c7ekme Se\u00e7enekleri:<\/strong> Kripto paralar dahil 100'den fazla y\u00f6ntem<\/li> <li><strong>Kullan\u0131c\u0131 Dostu Platform:<\/strong> Hisse ticaretini \u00f6\u011frenen yeni ba\u015flayanlar i\u00e7in ideal<\/li> <li><strong>E\u011fitim Kaynaklar\u0131:<\/strong> Piyasa analizi ve ticaret ara\u00e7lar\u0131na eri\u015fim<\/li> <\/ul>  <h2>\ud83e\uddec 2025'te Structure Therapeutics: Biyoteknoloji Yenilik\u00e7isi<\/h2> <p>Structure Therapeutics Inc., 2016 y\u0131l\u0131nda kurulmu\u015f ve merkezi G\u00fcney San Francisco'da bulunan klinik a\u015famadaki bir biyofarmas\u00f6tik \u015firkettir. \u015eirket, metabolik ve kardiyopulmoner hastal\u0131klar i\u00e7in G-protein ba\u011fl\u0131 resept\u00f6rleri (GPCR) hedef alan oral k\u00fc\u00e7\u00fck molek\u00fcl terapiler geli\u015ftirmeye odaklanmaktad\u0131r.<\/p> <p>\u00d6nc\u00fc aday <strong>aleniglipron<\/strong> (GSBR-1290), obezite tedavisi i\u00e7in Faz 2b denemelerinde olan oral bir GLP-1 resept\u00f6r agonistidir. \u015eirket, ACCESS ve ACCESS II \u00e7al\u0131\u015fmalar\u0131n\u0131n kay\u0131tlar\u0131n\u0131 tamamlad\u0131 ve 2025 sonuna kadar ana verilerin a\u00e7\u0131klanmas\u0131 beklenmektedir (<a href=\"https:\/\/trial.medpath.com\/news\/f4f0d98090a52484\/structure-therapeutics-advances-oral-obesity-drug-programs-with-completed-enrollment-in-key-aleniglipron-trials\">Klinik Deneme G\u00fcncellemesi<\/a>).<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Structure Therapeutics, Amerikan Diyabet Derne\u011fi'nin 85. Bilimsel Oturumlar\u0131nda, oral tedavisinin d\u00fcnya \u00e7ap\u0131nda milyonlarca diyabet ve obezite hastas\u0131nda i\u011fne korkusunu ortadan kald\u0131rabilece\u011fini g\u00f6steren \u00e7\u0131\u011f\u0131r a\u00e7an ara\u015ft\u0131rmalar\u0131yla man\u015fetlere \u00e7\u0131kt\u0131!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Structure Therapeutics Hisse Senedi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Structure Therapeutics Inc. (GPCR), NASDAQ borsas\u0131nda <strong>19,37 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize <strong>13 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin &#8211; \u015firketin bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn. Bu tarih, klinik deneme g\u00fcncellemeleri ve finansal performansa ba\u011fl\u0131 olarak hisse fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir.<\/p>\n<p><strong>13 Kas\u0131m Neden \u00d6nemli:<\/strong><br \/> 6 A\u011fustos 2025 tarihli \u00f6nceki kazan\u00e7 raporu, 2024&#8217;te 22,1 milyon dolardan 54,7 milyon dolara y\u00fckselen Ar-Ge harcamalar\u0131n\u0131 ve 61,7 milyon dolarl\u0131k net zarar\u0131 g\u00f6sterdi. Zararlar\u0131na ra\u011fmen, \u015firket 786,5 milyon dolarl\u0131k g\u00fc\u00e7l\u00fc bir nakit pozisyonuna sahip ve operasyonlar\u0131 2027&#8217;ye kadar finanse etmesi bekleniyor (<a href=\"https:\/\/www.stocktitan.net\/news\/GPCR\/structure-therapeutics-reports-second-quarter-2025-financial-results-lhkttczruz5p.html\">2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/a>).<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd0d Klinik Haberlerine Tarihsel Fiyat Tepkisi<\/h2>\n<p>GPCR gibi biyoteknoloji hisseleri, klinik deneme duyurular\u0131 etraf\u0131nda genellikle \u00f6nemli fiyat hareketleri ya\u015far. \u0130\u015fte hisse senedinin son geli\u015fmelere verdi\u011fi tepkiler:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Fiyat De\u011fi\u015fimi<\/th>\n<th>Etki S\u00fcresi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7 A\u00e7\u0131klamas\u0131<\/td>\n<td>-%8 (takip eden hafta)<\/td>\n<td>2 hafta<\/td>\n<\/tr>\n<tr>\n<td>Haz 2025<\/td>\n<td>ADA Bilimsel Oturumlar\u0131<\/td>\n<td>+%12<\/td>\n<td>3 g\u00fcn<\/td>\n<\/tr>\n<tr>\n<td>Nis 2025<\/td>\n<td>Klinik Program Geni\u015flemesi<\/td>\n<td>+%15<\/td>\n<td>1 hafta<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>Faz 2 Deneme G\u00fcncellemeleri<\/td>\n<td>+%22<\/td>\n<td>10 g\u00fcn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Model, olumlu klinik geli\u015fmelerin genellikle anl\u0131k fiyat s\u0131\u00e7ramalar\u0131na yol a\u00e7t\u0131\u011f\u0131n\u0131, finansal sonu\u00e7lar\u0131n ise daha \u00f6l\u00e7\u00fcl\u00fc tepkiler yaratt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Performans Analizi<\/h2>\n<p>Structure Therapeutics son alt\u0131 ayda olduk\u00e7a dalgal\u0131 bir seyir izledi:<\/p>\n<ul>\n<li><strong>\u015eubat 2025:<\/strong> Hisse 31,33 $ ile zirve yapt\u0131ktan sonra d\u00fc\u015ft\u00fc<\/li>\n<li><strong>Mart 2025:<\/strong> Piyasa volatilitesi nedeniyle 17,24 $ seviyesine geriledi<\/li>\n<li><strong>Nisan 2025:<\/strong> 13,22 $ ile dip yapt\u0131 ve ard\u0131ndan g\u00fc\u00e7l\u00fc bir toparlanma ya\u015fad\u0131<\/li>\n<li><strong>May\u0131s-Haziran 2025:<\/strong> 21-23 $ aral\u0131\u011f\u0131nda istikrar sa\u011flad\u0131<\/li>\n<li><strong>Temmuz-A\u011fustos 2025:<\/strong> 18-20 $ aras\u0131nda i\u015flem g\u00f6r\u00fcrken son d\u00f6nemde art\u0131\u015f ya\u015fand\u0131<\/li>\n<\/ul>\n<p>Genel trend, \u015eubat zirvesinden itibaren <strong>%35 d\u00fc\u015f\u00fc\u015f<\/strong> g\u00f6sterse de, hisse son bir ayda <strong>%7,81 kazan\u00e7<\/strong> sa\u011flad\u0131 (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/structure-therapeutics-nasdaqgpcr-shares-gap-up-still-a-buy-2025-08-19\/\">Son Performans<\/a>). Bu volatilite, klinik a\u015famadaki biyoteknoloji \u015firketleri i\u00e7in tipiktir ve \u00f6nemli veri a\u00e7\u0131klamalar\u0131n\u0131 beklerken g\u00f6r\u00fcl\u00fcr.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Analist konsens\u00fcs\u00fc ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak beklentiler \u015funlard\u0131r:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu:<\/strong> 50-75 $ aral\u0131\u011f\u0131 (klinik verilere ba\u011fl\u0131 olarak)<\/li>\n<li><strong>2026 Projeksiyonu:<\/strong> 75-90 $ (Faz 3 ba\u015flang\u0131c\u0131 bekleniyor)<\/li>\n<li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc:<\/strong> 120-150 $ (potansiyel d\u00fczenleyici ba\u015fvurular)<\/li>\n<li><strong>2030 Vizyonu:<\/strong> 200 $+ (ticarile\u015fme a\u015famas\u0131)<\/li>\n<\/ul>\n<p>Ortalama analist fiyat hedefi <strong>75,63 $<\/strong> olup, mevcut seviyelerden <strong>%285 y\u00fckseli\u015f potansiyeli<\/strong> sunmaktad\u0131r (<a href=\"https:\/\/stockanalysis.com\/stocks\/gpcr\/forecast\/\">Analist Konsens\u00fcs\u00fc<\/a>). \u00c7o\u011fu analist &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesi vermekte ve sadece olumlu \u00f6nerilerde bulunmaktad\u0131r.<\/p>\n<p><strong>Karar: AL<\/strong> &#8211; Risk-getiri oran\u0131, \u00f6zellikle \u00f6nemli klinik veri a\u00e7\u0131klamalar\u0131ndan \u00f6nce yat\u0131r\u0131m\u0131 desteklemektedir.<\/p>\n<h2>\u26a0\ufe0f Dikkate Al\u0131nmas\u0131 Gereken Yat\u0131r\u0131m Riskleri<\/h2>\n<p>Structure Therapeutics Inc. (GPCR) hissesine yat\u0131r\u0131m yapmadan \u00f6nce \u015fu riskleri anlay\u0131n:<\/p>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131:<\/strong> \u00d6nc\u00fc ila\u00e7 aleniglipron, Faz 2 veya Faz 3 denemelerinde ba\u015far\u0131s\u0131z olabilir<\/li>\n<li><strong>D\u00fczenleyici Engeller:<\/strong> FDA onay\u0131 yeni ila\u00e7lar i\u00e7in asla garanti de\u011fildir<\/li>\n<li><strong>Rekabet:<\/strong> Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri benzer oral GLP-1 ila\u00e7lar\u0131 geli\u015ftiriyor<\/li>\n<li><strong>Nakit T\u00fcketimi:<\/strong> \u00c7eyrek bazda 61,7 milyon dolarl\u0131k zarar, dikkatli sermaye y\u00f6netimi gerektirir<\/li>\n<li><strong>Piyasa Volatilitesi:<\/strong> Biyoteknoloji hisseleri tek bir haberle %20+ dalgalanabilir<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 2025 Yat\u0131r\u0131m\u0131 \u0130\u00e7in Olumlu Sinyaller<\/h2>\n<p>Risklere ra\u011fmen, yat\u0131r\u0131m i\u00e7in destekleyen birka\u00e7 fakt\u00f6r vard\u0131r:<\/p>\n<ul>\n<li><strong>786,5 Milyon $ Nakit Yedek:<\/strong> 2027&#8217;ye kadar operasyonlar\u0131 finanse eder, sermaye art\u0131r\u0131m\u0131 gerektirmez<\/li>\n<li><strong>Oral \u0130la\u00e7 Avantaj\u0131:<\/strong> Enjekte edilebilir rakiplere kar\u015f\u0131 potansiyel oyun de\u011fi\u015ftirici<\/li>\n<li><strong>Geni\u015fleyen Klinik Program:<\/strong> Rekabet\u00e7i konumu g\u00fc\u00e7lendiren \u00fc\u00e7 yeni klinik \u00e7al\u0131\u015fma<\/li>\n<li><strong>Analist Deste\u011fi:<\/strong> %95 al\u0131m \u00f6nerisi ve y\u00fcksek fiyat hedefleri<\/li>\n<li><strong>Piyasa Zamanlamas\u0131:<\/strong> 2025 sonuna kadar beklenen \u00f6nemli veriler b\u00fcy\u00fcmeyi tetikleyebilir<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-5&#8217;ini y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131r\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> T\u00fcm yat\u0131r\u0131m\u0131 tek seferde de\u011fil, par\u00e7a par\u00e7a yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun:<\/strong> Daha iyi giri\u015f noktalar\u0131 i\u00e7in 18 $ alt\u0131 d\u00fc\u015f\u00fc\u015fleri takip edin<\/li>\n<li><strong>Volatiliteye Haz\u0131rlan\u0131n:<\/strong> Hem olumlu hem olumsuz haberler i\u00e7in plan\u0131n\u0131z olsun<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc:<\/strong> &#8220;Biyoteknoloji hisseleriyle ticaret yapmak, fl\u00f6rt etmek gibidir &#8211; Faz 3 sonu\u00e7lar\u0131 gelene kadar heyecan vericidir. Her zaman bir \u00e7\u0131k\u0131\u015f stratejiniz olsun!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeli hisseleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Risk alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;GPCR&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>\u0130\u015flem \u00f6ncesi komisyon \u00fccretlerini kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2>\n<p>Structure Therapeutics Inc. (GPCR) hisseleri nas\u0131l al\u0131n\u0131r diye d\u00fc\u015f\u00fcnenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma:<\/strong> Ticarete ba\u015flamak i\u00e7in sadece 5 $<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama:<\/strong> Tek belge y\u00fcklemesi ile KYC tamamlan\u0131r<\/li>\n<li><strong>\u00c7oklu Para \u00c7ekme Se\u00e7enekleri:<\/strong> Kripto paralar dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<li><strong>Kullan\u0131c\u0131 Dostu Platform:<\/strong> Hisse ticaretini \u00f6\u011frenen yeni ba\u015flayanlar i\u00e7in ideal<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131:<\/strong> Piyasa analizi ve ticaret ara\u00e7lar\u0131na eri\u015fim<\/li>\n<\/ul>\n<h2>\ud83e\uddec 2025&#8217;te Structure Therapeutics: Biyoteknoloji Yenilik\u00e7isi<\/h2>\n<p>Structure Therapeutics Inc., 2016 y\u0131l\u0131nda kurulmu\u015f ve merkezi G\u00fcney San Francisco&#8217;da bulunan klinik a\u015famadaki bir biyofarmas\u00f6tik \u015firkettir. \u015eirket, metabolik ve kardiyopulmoner hastal\u0131klar i\u00e7in G-protein ba\u011fl\u0131 resept\u00f6rleri (GPCR) hedef alan oral k\u00fc\u00e7\u00fck molek\u00fcl terapiler geli\u015ftirmeye odaklanmaktad\u0131r.<\/p>\n<p>\u00d6nc\u00fc aday <strong>aleniglipron<\/strong> (GSBR-1290), obezite tedavisi i\u00e7in Faz 2b denemelerinde olan oral bir GLP-1 resept\u00f6r agonistidir. \u015eirket, ACCESS ve ACCESS II \u00e7al\u0131\u015fmalar\u0131n\u0131n kay\u0131tlar\u0131n\u0131 tamamlad\u0131 ve 2025 sonuna kadar ana verilerin a\u00e7\u0131klanmas\u0131 beklenmektedir (<a href=\"https:\/\/trial.medpath.com\/news\/f4f0d98090a52484\/structure-therapeutics-advances-oral-obesity-drug-programs-with-completed-enrollment-in-key-aleniglipron-trials\">Klinik Deneme G\u00fcncellemesi<\/a>).<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> Structure Therapeutics, Amerikan Diyabet Derne\u011fi&#8217;nin 85. Bilimsel Oturumlar\u0131nda, oral tedavisinin d\u00fcnya \u00e7ap\u0131nda milyonlarca diyabet ve obezite hastas\u0131nda i\u011fne korkusunu ortadan kald\u0131rabilece\u011fini g\u00f6steren \u00e7\u0131\u011f\u0131r a\u00e7an ara\u015ft\u0131rmalar\u0131yla man\u015fetlere \u00e7\u0131kt\u0131!<\/p>\n"},"faq":[{"question":"Structure Therapeutics Inc. (GPCR) hisseleri nereden al\u0131nabilir?","answer":"Structure Therapeutics Inc. (GPCR) hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"Structure Therapeutics hisselerine yat\u0131r\u0131m yapman\u0131n riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, d\u00fczenleyici onay engelleri, rekabet, y\u00fcksek nakit t\u00fcketimi ve piyasa volatilitesi bulunmaktad\u0131r."},{"question":"Structure Therapeutics hisselerinin fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 50-75 $, 2030 y\u0131l\u0131nda ise 200 $ ve \u00fczeri fiyatlar beklenmektedir."},{"question":"Yeni ba\u015flayan biri Structure Therapeutics hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131yla ba\u015flayarak, dolar maliyet ortalamas\u0131 yaparak, fiyat uyar\u0131lar\u0131 kurarak ve volatiliteye haz\u0131rl\u0131kl\u0131 olarak yat\u0131r\u0131m yap\u0131lmas\u0131 \u00f6nerilir."},{"question":"Pocket Option platformu Structure Therapeutics hisseleri i\u00e7in neden tercih edilir?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7oklu para \u00e7ekme se\u00e7enekleri, kullan\u0131c\u0131 dostu aray\u00fcz ve e\u011fitim kaynaklar\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in cazip bir platformdur."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Structure Therapeutics Inc. (GPCR) hisseleri nereden al\u0131nabilir?","answer":"Structure Therapeutics Inc. (GPCR) hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"Structure Therapeutics hisselerine yat\u0131r\u0131m yapman\u0131n riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, d\u00fczenleyici onay engelleri, rekabet, y\u00fcksek nakit t\u00fcketimi ve piyasa volatilitesi bulunmaktad\u0131r."},{"question":"Structure Therapeutics hisselerinin fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 50-75 $, 2030 y\u0131l\u0131nda ise 200 $ ve \u00fczeri fiyatlar beklenmektedir."},{"question":"Yeni ba\u015flayan biri Structure Therapeutics hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131yla ba\u015flayarak, dolar maliyet ortalamas\u0131 yaparak, fiyat uyar\u0131lar\u0131 kurarak ve volatiliteye haz\u0131rl\u0131kl\u0131 olarak yat\u0131r\u0131m yap\u0131lmas\u0131 \u00f6nerilir."},{"question":"Pocket Option platformu Structure Therapeutics hisseleri i\u00e7in neden tercih edilir?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7oklu para \u00e7ekme se\u00e7enekleri, kullan\u0131c\u0131 dostu aray\u00fcz ve e\u011fitim kaynaklar\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in cazip bir platformdur."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T09:05:40+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T09:05:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/\",\"name\":\"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-25T09:05:40+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T09:05:40+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T09:05:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/","name":"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-25T09:05:40+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-structure-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Structure Therapeutics Inc. (GPCR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Structure Therapeutics Inc. (GPCR) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":345913,"slug":"how-to-buy-structure-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":345916,"slug":"how-to-buy-structure-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Structure Therapeutics Inc. (GPCR) - Investimento em a\u00e7\u00f5es da Structure Therapeutics Inc. (GPCR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-structure-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/345915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=345915"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/345915\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=345915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=345915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=345915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}